Immuno-Oncology Pipeline

OSE Immunotherapeutics’ immuno-oncology pipeline is comprised of four programs, three of which are currently in clinical status.

The most advanced program is its Phase 3 trial with TEDOPI^®, a patented combination of 10 neo-epitopes, evaluated in HLA-A2 positive patients with non-small cell lung cancer (NSCLC) after failure of previous PD-1/PD-L1 checkpoint inhibitor treatment.

Tedopi® has shown positive Step-1 Phase 3 results of its Atalante 1 trial with a significant increase to overall survival and good safety profile.

A Phase 2 is ongoing in pancreatic cancer in collaboration with the GERCOR, a leading clinical research association that includes 300 cancer centers in France.

OSE Immunotherapeutics is also investigating BI 765063 (OSE-172), a first-in-class myeloid checkpoint inhibitor targeting the SIRPα / CD47 receptor pathway. BI 765063 is currently under Phase 1 clinical trial in advanced solid tumors under a license and collaboration agreement with Boehringer Ingelheim .

The Company develops a bispecific fusion protein platform (BiCKI®) built on the key backbone component anti-PD-1 (OSE-279), a novel standard of care treatment in oncology and paired with innovative immunotherapy targets. The BiCKI® platform strives to inhibit key immune checkpoints while simultaneously delivering intratumoral cytokines with Treg modulating function and/or increasing exhausted T cell responses.

Several new pipeline candidates should emerge in the near future in the immuno-oncology area.